Case-Based Roundtable Meetings Spotlight June 2021: Solid Tumors

Roundtable Discussion: Brose Explores Selpercatinib and Pralsetinib in MTC

July 06, 2021

Clinical Articles

Both selpercatinib and pralsetinib are FDA-approved therapies for RET-altered medullary thyroid cancer. The research supporting both agents and the experience with their use in clinical practice was the topic of a recent Case-Based Roundtable event moderated by Marcia S. Brose, MD, PhD.

Multiple Agents Prove Useful in RET-Mutated Thyroid Cancer

June 24, 2021

Clinical Articles

Many options are available for the treatment of RET-mutated thyroid cancer. During a Targeted Oncology Case-Based Roundtable event, Francis Paul Worden, MD, discussed the case of a 58-year-old patients who first presented with solitary nodule on the neck, occasional shortness of breath, and intermittent excessive fatigue.